M. Brambilla

P1.17.44 Multiomic Interaction Among Host and Tumor Immunity for Chemo De-Escalation. People Phase II Trial, First Line Pembrolizumab in Low PD-L1 NSCLC

L Invernizzi, G. Farhikhteh, Alessandra Rigamonti, Cecilia Silvestri et autres

it, us (code pays fourni par la source)

87P: Genomic alterations and resistance mechanisms in ALK-rearranged non-small cell lung cancer: Insights from NGS profiling and clinical outcomes

P. Ambrosini, Stefano Marchesi, M. Brambilla, Simone Rota et autres

it (code pays fourni par la source)

407P: Dissecting clinicopathologic features and treatment response in patients with LKB1-inactive NSCLC

G. Di Liberti, M. Occhipinti, M. Brambilla, Claudia Proto et autres

it (code pays fourni par la source)

Data analytics for real-world data integration in TKI-treated NSCLC patients using electronic health records

L. Mazzeo, F Corso, Paolo Baili, Fabio Scotti et autres

Background: Real-world data (RWD) are routinely collected in clinical practice during therapeutic interventions. Data warehouses (DWHs) represent the primary source of RWD in which electronic health records (EHRs) can be rapidly analyzed via natural language processing. This study illustrates an analytic framework …

it (code pays fourni par la source)

EP.12A.05 Evaluation of the Role of VAF/cellularity as Proxy of Gene Aberration in EGFR Mutated Advanced NSCLC During Osimertinib

M. Brambilla, Daniele Lorenzini, Giovanna Di Nardo, M. Occhipinti et autres

gb, it (code pays fourni par la source)

68P OncoMutational ratio on ctDNA: A potential novel biomarker in NSCLC

P. Ambrosini, L. Provenzano, A. Bottiglieri, A. Spagnoletti et autres

it (code pays fourni par la source)